Details of the Drug

General Information of Drug (ID: DMS7T13)

Drug Name

Meclizine

Synonyms

Ancolan; Ancolon; Antivert; Bonadettes; Bonine; Calmonal; Chiclida; Diadril; Histamethine; Histamethizine; Histametizine; Histametizyn; Histametizyne; Itinerol; Marex; Meclicot; Meclozina; Meclozine; Meclozinum; Medivert; Monamine; Navicalm; Nevidoxine; Parachloramine; Peremesin; Postafene; Ravelon; Sabari; Siguran; Subari; Suprimal; Travelon; Veritab; Vomisseis; Vomissels; Dramamine II; Meclizine Hcl; UCB 170; UCB 5052; UCB 5062; Antivert (TN); Antivert/25; Antivert/50; Bonamine (TN); Bonine (TN); Meclizine [INN:BAN]; Meclozina [INN-Spanish]; Meclozine (BAN); Meclozinum [INN-Latin]; Neo-istafene; Neo-suprimal; Neo-suprimel; Nevidoxine (TN); Postafen (TN); Sea-Legs; Ru-Vert-M; U. C. B. 5062; U.C.B. 5062; (+-)-Meclizine; 1-((4-Chlorophenyl)phenylmethyl)-4-((3-methylphenyl)methyl)piperazine; 1-(p-Chloro-.alpha.-phenylbenzyl)-4-(m-methylbenzyl)piperazine; 1-(p-Chloro-alpha-phenylbenzyl)-4-(m-methylbenzyl)piperazine; 1-(p-Chlorobenzhydryl)-4-(m-methylbenzyl)diethylenediamine; 1-(p-Chlorobenzhydryl)-4-(m-methylbenzyl)piperazine; 1-[(4-chlorophenyl)(phenyl)methyl]-4-[(3-methylphenyl)methyl]piperazine; 1-[(4-chlorophenyl)-phenylmethyl]-4-[(3-methylphenyl)methyl]piperazine; 1-p-Chlorobenzhydryl-4-m-methylbenzylpiperazine

Indication

Disease Entry	ICD 11	Status	REF
Dizziness	MB48	Approved	[1]

Therapeutic Class

Antiallergic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

390.9

Topological Polar Surface Area (xlogp)

5.8

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 3 h [2]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 5 - 6 hours [4]
Metabolism: The drug is metabolized via the hepatic CYP2D6 enzyme [5]

Chemical Identifiers

Formula: C25H27ClN2
IUPAC Name: 1-[(4-chlorophenyl)-phenylmethyl]-4-[(3-methylphenyl)methyl]piperazine
Canonical SMILES: CC1=CC(=CC=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl
InChI: InChI=1S/C25H27ClN2/c1-20-6-5-7-21(18-20)19-27-14-16-28(17-15-27)25(22-8-3-2-4-9-22)23-10-12-24(26)13-11-23/h2-13,18,25H,14-17,19H2,1H3
InChIKey: OCJYIGYOJCODJL-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4034
ChEBI ID: CHEBI:6709
CAS Number: 569-65-3
DrugBank ID: DB00737
TTD ID: D0T1XW
VARIDT ID: DR00977
INTEDE ID: DR1006
ACDINA ID: D00387

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Orphan nuclear receptor NR1I3 (NR1I3)	TTRANFM	NR1I3_HUMAN	Modulator	[6]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6)_{Main DME}	DECB0K3	CP2D6_HUMAN	Substrate	[7]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Meclizine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Bethanechol	DMCLHO0	Moderate	Antagonize the effect of Meclizine when combined with Bethanechol.	Abnormal micturition [MF50]	[22]
Scopolamine	DMOM8AL	Moderate	Additive anticholinergic effects by the combination of Meclizine and Scopolamine.	Addictive disorder [6C50-6C5Z]	[23]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Meclizine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[24]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Meclizine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[24]
Tripelennamine	DMZBU15	Moderate	Additive anticholinergic effects by the combination of Meclizine and Tripelennamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[23]
Memantine	DMD9WSC	Moderate	Additive anticholinergic effects by the combination of Meclizine and Memantine.	Alzheimer disease [8A20]	[23]
Rivastigmine	DMG629M	Moderate	Antagonize the effect of Meclizine when combined with Rivastigmine.	Alzheimer disease [8A20]	[25]
Donepezil	DMIYG7Z	Moderate	Antagonize the effect of Meclizine when combined with Donepezil.	Alzheimer disease [8A20]	[25]
Desipramine	DMT2FDC	Moderate	Additive anticholinergic effects by the combination of Meclizine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[23]
Loperamide	DMOJZQ9	Moderate	Additive antimotility effects by the combination of Meclizine and Loperamide.	Bowel habit change [ME05]	[26]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Meclizine when combined with Acetylcholine.	Cataract [9B10]	[27]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Meclizine and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[28]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Meclizine and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[28]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Meclizine and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[28]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Meclizine and Olopatadine.	Conjunctiva disorder [9A60]	[29]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Meclizine and Ethanol.	Cystitis [GC00]	[30]
Cyclobenzaprine	DM1YBRM	Moderate	Additive anticholinergic effects by the combination of Meclizine and Cyclobenzaprine.	Depression [6A70-6A7Z]	[23]
Isocarboxazid	DMAF1NB	Minor	Additive anticholinergic effects by the combination of Meclizine and Isocarboxazid.	Depression [6A70-6A7Z]	[23]
Tranylcypromine	DMGB5RE	Minor	Additive anticholinergic effects by the combination of Meclizine and Tranylcypromine.	Depression [6A70-6A7Z]	[23]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Meclizine and OPC-34712.	Depression [6A70-6A7Z]	[23]
Phenelzine	DMHIDUE	Minor	Additive anticholinergic effects by the combination of Meclizine and Phenelzine.	Depression [6A70-6A7Z]	[23]
Clomipramine	DMINRKW	Moderate	Additive anticholinergic effects by the combination of Meclizine and Clomipramine.	Depression [6A70-6A7Z]	[23]
Doxepin	DMPI98T	Moderate	Additive anticholinergic effects by the combination of Meclizine and Doxepin.	Depression [6A70-6A7Z]	[23]
Maprotiline	DMPWB7T	Moderate	Additive anticholinergic effects by the combination of Meclizine and Maprotiline.	Depression [6A70-6A7Z]	[23]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Meclizine and Esketamine.	Depression [6A70-6A7Z]	[31]
Oxybutynine	DMJPBAX	Moderate	Additive anticholinergic effects by the combination of Meclizine and Oxybutynine.	Discovery agent [N.A.]	[23]
Zonisamide	DM0DTF7	Major	Increased risk of hyperpyrexia by the combination of Meclizine and Zonisamide.	Epilepsy/seizure [8A61-8A6Z]	[32]
Solifenacin	DMG592Q	Moderate	Additive anticholinergic effects by the combination of Meclizine and Solifenacin.	Functional bladder disorder [GC50]	[23]
Propantheline	DM2EN6G	Moderate	Additive anticholinergic effects by the combination of Meclizine and Propantheline.	Gastric ulcer [DA60]	[23]
Pilocarpine	DMV9ADG	Moderate	Antagonize the effect of Meclizine when combined with Pilocarpine.	Glaucoma [9C61]	[22]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Meclizine caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[33]
Amantadine	DMS3YE9	Moderate	Additive anticholinergic effects by the combination of Meclizine and Amantadine.	Influenza [1E30-1E32]	[34]
Propiomazine	DMKY8V1	Moderate	Additive anticholinergic effects by the combination of Meclizine and Propiomazine.	Insomnia [7A00-7A0Z]	[23]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Meclizine and ITI-007.	Insomnia [7A00-7A0Z]	[23]
R0-93877	DMM4U9G	Moderate	Antagonize the effect of Meclizine when combined with R0-93877.	Irritable bowel syndrome [DD91]	[35]
Clidinium	DMUMQZ0	Moderate	Additive anticholinergic effects by the combination of Meclizine and Clidinium.	Irritable bowel syndrome [DD91]	[23]
Dicyclomine	DMZSDGX	Moderate	Additive anticholinergic effects by the combination of Meclizine and Dicyclomine.	Irritable bowel syndrome [DD91]	[23]
Physostigmine	DM2N0TO	Moderate	Antagonize the effect of Meclizine when combined with Physostigmine.	Lips/oral mucosa miscellaneous disorder [DA02]	[27]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Meclizine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[36]
Dacomitinib	DMOH8VY	Moderate	Decreased metabolism of Meclizine caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[37]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Meclizine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[38]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Meclizine and Lasmiditan.	Migraine [8A80]	[39]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Meclizine and Flibanserin.	Mood disorder [6A60-6E23]	[40]
Panobinostat	DM58WKG	Moderate	Decreased metabolism of Meclizine caused by Panobinostat mediated inhibition of CYP450 enzyme.	Multiple myeloma [2A83]	[41]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Meclizine and Thalidomide.	Multiple myeloma [2A83]	[42]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Meclizine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[36]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Meclizine and Phenindamine.	Nasopharyngitis [CA00]	[23]
Dimenhydrinate	DM264B3	Moderate	Additive anticholinergic effects by the combination of Meclizine and Dimenhydrinate.	Nausea/vomiting [MD90]	[23]
Promethazine	DM6I5GR	Moderate	Additive anticholinergic effects by the combination of Meclizine and Promethazine.	Nausea/vomiting [MD90]	[23]
Rolapitant	DM8XP26	Moderate	Decreased metabolism of Meclizine caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[43]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Meclizine and Cyclizine.	Nausea/vomiting [MD90]	[23]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Meclizine and Flavoxate.	Pain [MG30-MG3Z]	[23]
Biperiden	DME78OA	Moderate	Additive anticholinergic effects by the combination of Meclizine and Biperiden.	Parkinsonism [8A00]	[23]
Orphenadrine	DMW542E	Moderate	Additive anticholinergic effects by the combination of Meclizine and Orphenadrine.	Parkinsonism [8A00]	[23]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Meclizine and Methylscopolamine.	Peptic ulcer [DA61]	[23]
Levomepromazine	DMIKFEL	Moderate	Additive anticholinergic effects by the combination of Meclizine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[23]
Quetiapine	DM1N62C	Moderate	Additive anticholinergic effects by the combination of Meclizine and Quetiapine.	Schizophrenia [6A20]	[23]
Mesoridazine	DM2ZGAN	Moderate	Additive anticholinergic effects by the combination of Meclizine and Mesoridazine.	Schizophrenia [6A20]	[23]
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Meclizine and Aripiprazole.	Schizophrenia [6A20]	[23]
Iloperidone	DM6AUFY	Moderate	Additive anticholinergic effects by the combination of Meclizine and Iloperidone.	Schizophrenia [6A20]	[23]
Paliperidone	DM7NPJS	Moderate	Additive anticholinergic effects by the combination of Meclizine and Paliperidone.	Schizophrenia [6A20]	[23]
Perphenazine	DMA4MRX	Moderate	Additive anticholinergic effects by the combination of Meclizine and Perphenazine.	Schizophrenia [6A20]	[23]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Meclizine and Molindone.	Schizophrenia [6A20]	[23]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Meclizine and Thiothixene.	Schizophrenia [6A20]	[23]
Trifluoperazine	DMKBYWI	Moderate	Additive anticholinergic effects by the combination of Meclizine and Trifluoperazine.	Schizophrenia [6A20]	[23]
Asenapine	DMSQZE2	Moderate	Additive anticholinergic effects by the combination of Meclizine and Asenapine.	Schizophrenia [6A20]	[23]
Pimozide	DMW83TP	Moderate	Additive anticholinergic effects by the combination of Meclizine and Pimozide.	Schizophrenia [6A20]	[23]
Chlorpheniramine	DM5URA2	Moderate	Additive anticholinergic effects by the combination of Meclizine and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[23]
Methdilazine	DMAUHQX	Moderate	Additive anticholinergic effects by the combination of Meclizine and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[23]
Carbinoxamine	DMCT31R	Moderate	Additive anticholinergic effects by the combination of Meclizine and Carbinoxamine.	Vasomotor/allergic rhinitis [CA08]	[23]
Trimeprazine	DMEMV9D	Moderate	Additive anticholinergic effects by the combination of Meclizine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[24]
Brompheniramine	DMFOVSD	Moderate	Additive anticholinergic effects by the combination of Meclizine and Brompheniramine.	Vasomotor/allergic rhinitis [CA08]	[23]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Meclizine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[23]
-----------


⏷ Show the Full List of 73 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Acesulfame	E00341	36573	Flavoring agent
Allura red AC dye	E00338	33258	Colorant
Aspartame	E00402	134601	Flavoring agent
FD&C blue no. 1	E00263	19700	Colorant
Hydrazine yellow	E00409	164825	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Levomenthol	E00248	16666	Flavoring agent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium stearyl fumarate	E00545	23665634	lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite	E00392	104805	Diluent
Calcium hydrogenphosphate	E00294	24441	Diluent
Calcium stearate	E00244	15324	lubricant
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Dextrin	E00359	62698	Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Erythritol	E00410	222285	Diluent; Flavoring agent
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium sulfate	E00292	24436	Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 31 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Meclizine 25 mg tablet	25 mg	Chewable Tablet	Oral
Meclizine 12.5 mg tablet	12.5 mg	Oral Tablet	Oral
Meclizine 25 mg tablet	25 mg	Oral Tablet	Oral
Meclizine 25 mg tablet	25 mg	Disintegrating Oral Tablet	Oral
Meclizine 50 mg tablet	50 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	Antivert (meclizine hydrochloride) - Drug Summary - PDR.net
3	BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
4	FDA Approved Drug Products: ANTIVERT (meclizine) oral tablets
5	Nordt SP, Clark RF: Midazolam: a review of therapeutic uses and toxicity. J Emerg Med. 1997 May-Jun;15(3):357-65.
6	Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR). Drug Metab Rev. 2006;38(1-2):51-73.
7	Meclizine metabolism and pharmacokinetics: formulation on its absorption. J Clin Pharmacol. 2012 Sep;52(9):1343-9.
8	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
9	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
10	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
11	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
12	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
13	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
14	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
15	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
16	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
17	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
18	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
19	Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. J Biol Chem. 2003 May 9;278(19):17277-83.
20	The nuclear receptor CAR is a regulator of thyroid hormone metabolism during caloric restriction. J Biol Chem. 2004 May 7;279(19):19832-8.
21	Androstane metabolites bind to and deactivate the nuclear receptor CAR-beta. Nature. 1998 Oct 8;395(6702):612-5.
22	Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979): 199-255. [PMID: 376469]
23	Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
24	Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
25	Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
26	Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
27	Multum Information Services, Inc. Expert Review Panel.
28	Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
29	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
30	Linnoila M "Drug effects on psychomotor skills related to driving: interaction of atropine, glycopyrrhonium and alcohol." Eur J Clin Pharmacol 6 (1973): 107-12. [PMID: 4588850]
31	Cerner Multum, Inc. "Australian Product Information.".
32	Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
33	Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
34	Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
35	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
36	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
37	Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
38	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
39	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
40	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
41	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
42	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
43	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.